Context Therapeutics Inc. Common Stock (CNTX)
Stock · NASDAQ · Health Care
$0.2438as of 10/16/2026
Price chart
Active signals
CNTX Signal Track Record
How signals performed across all stocks →What CNTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 48 | +1.5% | 50% | September 14, 2026 |
| Bollinger Band Breakout | 25 | -0.9% | 48% | August 5, 2026 |
| Bollinger Band Breakdown | 20 | -13.5% | 30% | September 28, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +16.0% | 83% | September 16, 2025 |
| Any 20-session window (baseline) | -2.4% | 46% |
Computed by MarketWall from daily closing prices since August 5, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15
- Website
- www.contexttherapeutics.com/
Fundamentals
- 1-day range
- $0.2221$0.27
- Market cap
- $46.31M
- P/E (trailing)
- —
- P/E (forward)
- -0.56
- EPS (trailing)
- $-0.48
- Dividend yield
- —
- Beta
- 1.77
- Avg. volume
- 1.57M
Forecasts
8 analyst ratings
Context Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CNTXContext Therapeutics Inc. Common Stock$0.244▲ 1.24%Market cap $46.31MP/E —$0.2358$3.62
- FLNAFilana Therapeutics Inc. Common Stock$0.7▼ 7.89%Market cap $46.33MP/E —$0.6701$2.27
- MREOMereo BioPharma Group plc American Depositary Shares$0.303▼ 1.94%Market cap $47.46MP/E —$0.2$2.37
- EDSAEdesa Biotech Inc. Common Shares$2.57▼ 3.75%Market cap $44.90MP/E —$0.72$20.32
- MCRBSeres Therapeutics Inc. Common Stock$2.46▼ 2.77%Market cap $48.42MP/E —$2.8$29.98
- KPTIKaryopharm Therapeutics Inc. Common Stock$0.39▲ 11.11%Market cap $44.19MP/E —$0.31$10.99
- TCRTAlaunos Therapeutics Inc. Common Stock$2.63▲ 20.64%Market cap $48.60MP/E —$0.719$4.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CNTX Context Therapeutics Inc. Common Stock | $46.31M | — | $0.244 | ▲ 1.24% | $0.2358$3.62 |
| FLNA Filana Therapeutics Inc. Common Stock | $46.33M | — | $0.7 | ▼ 7.89% | $0.6701$2.27 |
| MREO Mereo BioPharma Group plc American Depositary Shares | $47.46M | — | $0.303 | ▼ 1.94% | $0.2$2.37 |
| EDSA Edesa Biotech Inc. Common Shares | $44.90M | — | $2.57 | ▼ 3.75% | $0.72$20.32 |
| MCRB Seres Therapeutics Inc. Common Stock | $48.42M | — | $2.46 | ▼ 2.77% | $2.8$29.98 |
| KPTI Karyopharm Therapeutics Inc. Common Stock | $44.19M | — | $0.39 | ▲ 11.11% | $0.31$10.99 |
| TCRT Alaunos Therapeutics Inc. Common Stock | $48.60M | — | $2.63 | ▲ 20.64% | $0.719$4.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Kantoff Philip W. · June 24, 2026 · Grant45.0K
- West Linda · June 24, 2026 · Grant45.0K
- Pasternak Andy · June 24, 2026 · Grant45.0K
- Luke Nathaniel Walker · June 24, 2026 · Grant45.0K
- Smith Karen L. · June 24, 2026 · Grant45.0K
- Stacey Jennifer Evans · June 24, 2026 · Grant45.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 73.87M
- Total value held
- $193.20M
- Institutional holders
- 57
- Unknown10.68M
- Unknown7.42M
- Unknown7.42M
- Unknown6.96M
- Unknown5.25M
- Unknown5.09M
- Unknown5.00M
- Unknown3.80M
- Unknown3.43M
- Unknown2.95M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
CNTX appears on Yahoo's recent strong negative rating lists
Yahoo listed Context Therapeutics in its strong negative rating lists for October 13 and October 15. The inclusion reflects recent analyst concerns about the company's outlook. The stock is currently trading with a low RSI and near its identified support level, which aligns with the negative sentiment.
CNTX appears on Yahoo's recent strong negative rating lists. Yahoo listed Context Therapeutics in its strong negative rating lists for October 13 and October 15. The inclusion reflects recent analyst concerns about the company's outlook. The stock is currently trading with a low RSI and near its identified support level, which aligns with the negative sentiment.